Phase 4 N=51 Effects of AMP Application After Non-surgical Periodontal Therapy on Treatment of Periodontitis
Periodontitis
Primary: Periodontal Probing Depth — 2.5; 3.2; 3.4 millimeter
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=352 Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy
Psoriasis
Primary: Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 (Defined as at Least 90% Improvement in PASI From Baseline) in Intent to Treat Population at…
Phase 4 N=7 Predicting Inflammatory Skin Disease Response to IL-23 Blockade
Psoriasis Vulgaris
Primary: Psoriasis Area and Severity Index (PASI) Score — 3.9 score on a scale
Phase 4 N=459 FLUAD vs. FLUZONE HD Influenza Vaccine in Residents of Long Term Care
Flu
Primary: Overall Hemagglutinin Inhibition (HAI) H1N1 Titer Between FLUAD and FLUZONE HD at 1 Month Post-vaccination. — 213.4; 261.9; 70.5; 67.2 Titer
Phase 4 N=108 Pitocin or Oral Misoprostol for PROM IOL
PROM
Primary: Time From Induction of Labor (IOL) to Delivery — 18.1; 14.9 Hours
Phase 4 N=22 Effect of Dexmedetomidine of Gastrointestinal Motility
Anesthesia
Primary: Intra-anal Sphincter Pressure (IASP) 1 Minute After Dexmedetomidine Administration — 62.9 mmHg
Phase 4 N=102 Adductor Canal Block and IPACK Block vs. Isolated Adductor Canal Block for Post-Operative Analgesia Following ACL Reconstruction With Bone Patellar Tendon Bone Autograft:
Anterior Cruciate Ligament Rupture
Primary: Opioid Utilization in First 24 Hours Post-Surgery — 6.1; 10.7 morphine milligram equivalents
Phase 4 N=200 A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India
Pneumococcal Disease
Primary: Percentage of Participants With Prompted Local Reactions Within 7 Days After Vaccination — 1.5; 6.5; 63.0 Percentage
Phase 4 N=62 A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease
Thyroid Eye Disease · Chronic (Inactive) Thyroid Eye Disease
Primary: Change From Baseline in Proptosis of Study Eye at Week 24 — -2.41; -0.92 Millimieter (mm) — p=0.0004
Phase 4 N=310 Study to Evaluate the Safety and Clinical Efficacy of Augmentin® Extra Strength-600 in Children With Acute Otitis Media in India
Otitis Media · Infections, Respiratory Tract · Respiratory Tract Infections
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 10; 3; 3 Participants
Phase 4 N=100 Weight Loss Aid in an Exposed Population
Polybrominated Biphenyl Poisoning
Primary: Weight — 91.3; 92.3; 88.6; 87.4 kilograms (kg)
Phase 4 N=136 Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures
Urinary Tract Diseases
Primary: Total Opioid Consumption — 16.4; 15.3 morphine equivalent
Phase 4 N=12 The Influence of Menthol Gel During Exercise With Heat
Acute Exercise · Heat Exposure
Primary: Skin Blood Flow — 131.6; 119.2 arbitrary units — p=0.742
Phase 4 N=22 Use of Platelet-rich Plasma (PRP) Therapy in Patients With Brittle Nail Syndrome
Nail Diseases
Primary: Physician Global Improvement Assessment (PGIA) — 5; 2; 7; 1 Fingernails
Phase 4 N=25 A Study to Investigate the Effect of Roxadustat Versus Recombinant Human Erythropoietin (rHuEPO) on Oral Iron Absorption in Chinese Patients With Anemia of Chronic Kidney Disease (CKD)
Anemia of Chronic Kidney Disease
Primary: Difference From Baseline to Day 15 in Area Under Curve (AUC) of GI Iron Absorption (0-3 Hours) — 11.288; -0.259; 20.125; -1.625 gram*3hours/deciliter (g*3hr/dL) — p=0.212